Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02540278 · ClinicalTrials.gov registry record · NA
Evaluation of the Positive Prevention PLUS Program
A NA study, sponsored by California State University, San Bernardino.
- Completed
- Registry status
- NA
- Development phase
- 4,267
- Enrollment target
NCT02540278: Completed NA study, sponsored by California State University, San Bernardino.
NCT02540278 is a NA study that has completed, run by California State University, San Bernardino. The registered enrollment target is 4,267 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (204% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02540278, a NA study, has completed, sponsored by California State University, San Bernardino.
- COMPLETED
- Registry status
- NA
- Development phase
- 4,267 participants
- Enrollment target
Study Summary
This study aims to determine if the Positive Prevention PLUS teen pregnancy prevention program has an impact on abstinence, birth control use, and likelihood of becoming pregnant.
Primary Outcome
Ever had sex (Yes/No)
Interventions
- BEHAVIORAL Positive Prevention PLUS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,267 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-10 |
| Phase | NA |
What the finished NCT02540278 record still lists
NCT02540278 is an interventional study that assigns participants to a tested intervention. Its 4,267 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (204% higher).
The record links to 0 conditions, and to 1 intervention - of which Positive Prevention PLUS is the first listed.
NCT02540278 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02540278 about?
NCT02540278 is a clinical study titled "Evaluation of the Positive Prevention PLUS Program". This study aims to determine if the Positive Prevention PLUS teen pregnancy prevention program has an impact on abstinence, birth control use, and likelihood of becoming pregnant.
What is the current status of trial NCT02540278?
This trial is currently completed. It is a NA study. The enrollment target is 4,267 participants. The study started on 2013-08. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02540278?
The interventions under investigation include: Positive Prevention PLUS (BEHAVIORAL).
Who is sponsoring clinical trial NCT02540278?
This trial is sponsored by California State University, San Bernardino, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02540278's enrollment target sits among peer trials
4,267 30th of 2000 higher than 1,971 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05543616 · 4,292 participants · Phase 2
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
- NCT05774951 · 4,300 participants · Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- NCT06492616 · 4,220 participants · Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- NCT02693535 · 4,200 participants · Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia